Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Moleculin Biotech ( (MBRX) ) has provided an update.
Moleculin Biotech announced the online publication of preclinical data showing significant activity of Annamycin, a non-cardiotoxic anthracycline, in treating acute myeloid leukemia (AML) that is resistant to Ara-C and Venetoclax. The data, presented at the ASH Annual Meeting, highlights Annamycin’s potential as a game-changing treatment due to its favorable toxicity profile and synergy with Ara-C, achieving a 60% complete remission rate in clinical trials. The company is advancing Annamycin through a Phase 3 trial, with Annamycin holding Fast Track and Orphan Drug Designation from the FDA and EMA.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, is a next-generation anthracycline aimed at treating relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases without the cardiotoxicity associated with existing anthracyclines.
YTD Price Performance: -82.07%
Average Trading Volume: 42,343
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.93M
Learn more about MBRX stock on TipRanks’ Stock Analysis page.
